187 related articles for article (PubMed ID: 11982630)
1. Preferential alterations in the mesolimbic dopamine pathway of heterozygous reeler mice: an emerging animal-based model of schizophrenia.
Ballmaier M; Zoli M; Leo G; Agnati LF; Spano P
Eur J Neurosci; 2002 Apr; 15(7):1197-205. PubMed ID: 11982630
[TBL] [Abstract][Full Text] [Related]
2. Enhanced glutamatergic phenotype of mesencephalic dopamine neurons after neonatal 6-hydroxydopamine lesion.
Dal Bo G; Bérubé-Carrière N; Mendez JA; Leo D; Riad M; Descarries L; Lévesque D; Trudeau LE
Neuroscience; 2008 Sep; 156(1):59-70. PubMed ID: 18706980
[TBL] [Abstract][Full Text] [Related]
3. ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia.
Galter D; Buervenich S; Carmine A; Anvret M; Olson L
Neurobiol Dis; 2003 Dec; 14(3):637-47. PubMed ID: 14678778
[TBL] [Abstract][Full Text] [Related]
4. Decreased plasma membrane expression of striatal dopamine transporter in aging.
Salvatore MF; Apparsundaram S; Gerhardt GA
Neurobiol Aging; 2003 Dec; 24(8):1147-54. PubMed ID: 14643386
[TBL] [Abstract][Full Text] [Related]
5. Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections.
Ferrari R; Le Novère N; Picciotto MR; Changeux JP; Zoli M
Eur J Neurosci; 2002 Jun; 15(11):1810-8. PubMed ID: 12081661
[TBL] [Abstract][Full Text] [Related]
6. Alterations in the hippocampal and striatal catecholaminergic fiber densities of heterozygous reeler mice.
Nullmeier S; Panther P; Frotscher M; Zhao S; Schwegler H
Neuroscience; 2014 Sep; 275():404-19. PubMed ID: 24969133
[TBL] [Abstract][Full Text] [Related]
7. p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies.
Hirata H; Cadet JL
J Neurochem; 1997 Aug; 69(2):780-90. PubMed ID: 9231739
[TBL] [Abstract][Full Text] [Related]
8. Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area.
Adelbrecht C; Agid Y; Raisman-Vozari R
Brain Res Mol Brain Res; 1996 Dec; 43(1-2):291-300. PubMed ID: 9037545
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.
Han M; Huang XF; Deng C
Int J Neuropsychopharmacol; 2009 Aug; 12(7):941-52. PubMed ID: 19203411
[TBL] [Abstract][Full Text] [Related]
10. Neonatal phencyclidine treatment selectively attenuates mesolimbic dopamine function in adult rats as revealed by methamphetamine-induced behavior and c-fos mRNA expression in the brain.
Semba J; Tanaka N; Wakuta M; Suhara T
Synapse; 2001 Apr; 40(1):11-8. PubMed ID: 11170217
[TBL] [Abstract][Full Text] [Related]
11. The neonatal ventral hippocampal lesion model of schizophrenia: effects on dopamine and GABA mRNA markers in the rat midbrain.
Lipska BK; Lerman DN; Khaing ZZ; Weinberger DR
Eur J Neurosci; 2003 Dec; 18(11):3097-104. PubMed ID: 14656305
[TBL] [Abstract][Full Text] [Related]
12. Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat.
Shepard JD; Chuang DT; Shaham Y; Morales M
Psychopharmacology (Berl); 2006 May; 185(4):505-13. PubMed ID: 16555063
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of ascending dopamine projections to 6-hydroxydopamine in rats: effect of hypothermia.
Grant RJ; Clarke PB
Neuroscience; 2002; 115(4):1281-94. PubMed ID: 12453497
[TBL] [Abstract][Full Text] [Related]
14. Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia.
Rice MW; Roberts RC; Melendez-Ferro M; Perez-Costas E
Brain Struct Funct; 2016 Jan; 221(1):185-201. PubMed ID: 25269834
[TBL] [Abstract][Full Text] [Related]
15. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity.
Haber SN; Ryoo H; Cox C; Lu W
J Comp Neurol; 1995 Nov; 362(3):400-10. PubMed ID: 8576447
[TBL] [Abstract][Full Text] [Related]
16. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR.
Hurley MJ; Mash DC; Jenner P
Eur J Neurosci; 2003 Nov; 18(9):2668-72. PubMed ID: 14622169
[TBL] [Abstract][Full Text] [Related]
17. Region-specific alteration of GABAergic markers in the brain of heterozygous reeler mice.
Nullmeier S; Panther P; Dobrowolny H; Frotscher M; Zhao S; Schwegler H; Wolf R
Eur J Neurosci; 2011 Feb; 33(4):689-98. PubMed ID: 21226776
[TBL] [Abstract][Full Text] [Related]
18. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
19. Elevated D3 dopamine receptor mRNA in dopaminergic and dopaminoceptive regions of the rat brain in response to morphine.
Spangler R; Goddard NL; Avena NM; Hoebel BG; Leibowitz SF
Brain Res Mol Brain Res; 2003 Mar; 111(1-2):74-83. PubMed ID: 12654507
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptor signaling affects development and function of dopamine neurons - inhibition results in a schizophrenia-like syndrome in transgenic mice.
Klejbor I; Myers JM; Hausknecht K; Corso TD; Gambino AS; Morys J; Maher PA; Hard R; Richards J; Stachowiak EK; Stachowiak MK
J Neurochem; 2006 Jun; 97(5):1243-58. PubMed ID: 16524369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
